FCGR1A and rheumatoid arthritis: showed that Sinomenine (SIN), an anti-inflammatory drug used in RA treatment, attenuated CD64+ macrophages in synovial tissue and CD11b+F4/80+CD64+ resident macrophages in RA tissues and lymphoid organs, further supporting CD64 as a therapeutic target in RA (59).